14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
USLM vs UTMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Utah Medical Products Inc (UTMD) captures the overall head-to-head institutional edge over United States Lime & Minerals (USLM) on higher Unified Composite conviction (52.9/100 HOLD vs. 46.1/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, R&D & Supply-Chain Moat), while USLM wins 4–2 across the 6-pillar growth and valuation breakdown. USLM trades at $107.20 (18.5x Forward P/E, 41.2% operating margin) versus UTMD at $72.38 (13.0x Forward P/E, 34.3% operating margin).
Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. USLM 46.1/100 HOLD) and 0.23β · 33% Vol risk profile, whereas USLM leads top-line expansion (+4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: USLM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile UTMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on USLM vs UTMD. Trailing 12-month operating profitability (USLM 41.2% vs UTMD 34.3%) and valuation multiples (USLM 18.5x vs UTMD 13.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Building Materials value chain with $3.3B market capitalization and 41.2% operating margin.
OpEx & R&D Reinvestment13.2% of Rev ($50M)
90D Engineering Disclosures0 Published
UTMD Moat ProfileHigh-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $209.6M market capitalization and 34.3% operating margin.
OpEx & R&D Reinvestment23.4% of Rev ($8.2M)
90D Engineering Disclosures0 Published
Investor FAQ USLM vs UTMD Key Questions & Quantitative Answers
As of Nov 16, 2026, Utah Medical Products Inc (UTMD) captures the overall head-to-head institutional edge over United States Lime & Minerals (USLM) on higher Unified Composite conviction (52.9/100 HOLD vs. 46.1/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, R&D & Supply-Chain Moat), while USLM wins 4–2 across the 6-pillar growth and valuation breakdown. USLM trades at $107.20 (18.5x Forward P/E, 41.2% operating margin) versus UTMD at $72.38 (13.0x Forward P/E, 34.3% operating margin). Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. USLM 46.1/100 HOLD) and 0.23β · 33% Vol risk profile, whereas USLM leads top-line expansion (+4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: USLM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile UTMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
USLM leads the Growth & Scale pillar: USLM posts +4.1% YoY revenue growth and -2.2% YoY earnings growth on $381M TTM revenue (54.4% gross margin, 41.2% operating margin), compared with UTMD at -12.1% YoY revenue growth and +6.8% YoY earnings growth on $35M TTM revenue (57.7% gross margin, 34.3% operating margin). On trailing 12-month operating scale, USLM generates $381M in USD-normalized revenue versus $35M for UTMD. In operating R&D and SG&A reinvestment, USLM deploys 13.2% of Rev ($50M) (0 90-day corporate R&D disclosures) versus 23.4% of Rev ($8.2M) (0 disclosures) for UTMD.
UTMD screens cheaper on headline valuation multiples. USLM trades at 18.5x Forward P/E, 24.6x Trailing P/E, N/M PEG, and 8.6x EV/Revenue (48.1% EBITDA margin), whereas UTMD trades at 13.0x Forward P/E, 22.0x Trailing P/E, 4.25x PEG, and 6.0x EV/Revenue (38.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against USLM (20.0% ROE) versus UTMD (8.8% ROE) capital efficiency.
In options market volatility and institutional positioning, USLM carries 46.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.74β · 42% Vol realized risk). By comparison, UTMD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.23β · 33% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.